Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hyperlipoproteinemias

  Free Subscription


Articles published in J Lipid Res

Retrieve available abstracts of 20 articles:
HTML format



Single Articles


    February 2024
  1. CHACKERIAN B, Remaley AT
    PCSK9 Vaccines: A promising new strategy for the treatment of hypercholesterolemia?
    J Lipid Res. 2024 Feb 17:100524. doi: 10.1016/j.jlr.2024.100524.
    PubMed    


    January 2024
  2. SLIJKHUIS N, Razzi F, Korteland SA, Heijs B, et al
    Spatial Lipidomics of Coronary Atherosclerotic Plaque Development in a Familial Hypercholesterolemia Swine Model.
    J Lipid Res. 2024 Jan 19:100504. doi: 10.1016/j.jlr.2024.100504.
    PubMed     Abstract available


    December 2023
  3. CHAPMAN MJ, Orsoni A, Mellett NA, Nguyen A, et al
    Statin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia.
    J Lipid Res. 2023 Dec 29:100494. doi: 10.1016/j.jlr.2023.100494.
    PubMed     Abstract available


  4. MEDEIROS AM, Alves AC, Miranda B, Chora JR, et al
    Unravelling the genetic background of individuals with a clinical Familial Hypercholesterolemia phenotype.
    J Lipid Res. 2023 Dec 18:100490. doi: 10.1016/j.jlr.2023.100490.
    PubMed     Abstract available


  5. JAMES JK, Norland K, Johar AS, Kullo IJ, et al
    Deep generative models of LDLR protein structure to predict variant pathogenicity.
    J Lipid Res. 2023;64:100455.
    PubMed     Abstract available


    July 2023
  6. WANG Y, Kong L, Ye C, Dou C, et al
    Hypertriglyceridemic hyperapoB and the development and resolution of nonalcoholic fatty liver disease: A cohort study.
    J Lipid Res. 2023 Jul 20:100418. doi: 10.1016/j.jlr.2023.100418.
    PubMed     Abstract available


    November 2022
  7. SUCHOWERSKA AK, Stokman G, Palmer JT, Coghlan PA, et al
    A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo.
    J Lipid Res. 2022;63:100293.
    PubMed     Abstract available


    October 2022
  8. YUAN X, Bhat OM, Zou Y, Li X, et al
    Endothelial Acid Sphingomyelinase Promotes NLRP3 Inflammasome and Neointima Formation during Hypercholesterolemia.
    J Lipid Res. 2022 Oct 14:100298. doi: 10.1016/j.jlr.2022.100298.
    PubMed     Abstract available


  9. MOBILIA M, Whitus C, Karakashian A, Lu HS, et al
    Dennd5b deficient mice are resistant to PCSK9-induced hypercholesterolemia and diet-induced hepatic steatosis.
    J Lipid Res. 2022 Oct 12:100296. doi: 10.1016/j.jlr.2022.100296.
    PubMed     Abstract available


    September 2022
  10. OESTEREICH F, Yousefpour N, Yang E, Phenix J, et al
    The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain.
    J Lipid Res. 2022;63:100260.
    PubMed     Abstract available


    August 2022
  11. MITOK KA, Keller MP, Attie AD
    Sorting through the extensive and confusing roles of sortilin in metabolic disease.
    J Lipid Res. 2022;63:100243.
    PubMed     Abstract available


    June 2022
  12. CLARK JR, Gemin M, Youssef A, Marcovina SM, et al
    Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).
    J Lipid Res. 2022;63:100216.
    PubMed     Abstract available


    May 2022
  13. RODRIGUEZ-GUTIERREZ R, Gonzalez JG, Parmar D, Shaikh F, et al
    Saroglitazar is non-inferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
    J Lipid Res. 2022 May 20:100233. doi: 10.1016/j.jlr.2022.100233.
    PubMed     Abstract available


    March 2022
  14. GOMES D, Wang S, Goodspeed L, Turk KE, et al
    Comparison between genetic and pharmaceutical disruption of Ldlr expression for the development of atherosclerosis.
    J Lipid Res. 2022;63:100174.
    PubMed     Abstract available


    January 2022
  15. MORTON RE, Mihna D
    Apolipoprotein F concentration, activity, and the properties of LDL controlling ApoF activation in hyperlipidemic plasma.
    J Lipid Res. 2022 Jan 8:100166. doi: 10.1016/j.jlr.2021.100166.
    PubMed     Abstract available


    October 2021
  16. FUTEMA M, Taylor-Beadling A, Williams M, Humphries SE, et al
    Genetic testing for Familial Hypercholesterolaemia - Past, Present and Future.
    J Lipid Res. 2021 Oct 16:100139. doi: 10.1016/j.jlr.2021.100139.
    PubMed     Abstract available


  17. SEIDAH NG
    The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer.
    J Lipid Res. 2021 Oct 1:100130. doi: 10.1016/j.jlr.2021.100130.
    PubMed     Abstract available


    March 2021
  18. ROSENSON RS
    Existing and emerging therapies for the treatment of familial hypercholesterolemia.
    J Lipid Res. 2021 Mar 11:100060. doi: 10.1016/j.jlr.2021.100060.
    PubMed     Abstract available


  19. CHEMELLO K, Garcia-Nafria J, Gallo A, Martin C, et al
    Lipoprotein Metabolism in Familial Hypercholesterolemia.
    J Lipid Res. 2021 Mar 3:100062. doi: 10.1016/j.jlr.2021.100062.
    PubMed     Abstract available


    January 2021
  20. THOMPSON GR
    FH through the retrospectoscope.
    J Lipid Res. 2021;62:100036.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.